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Abstract
Background: In randomised trials of medical interventions, the most reliable analysis follows the intention-to-treat (ITT)
principle. However, the ITT analysis requires that missing outcome data have to be imputed. Different imputation
techniques may give different results and some may lead to bias. In anti-obesity drug trials, many data are usually missing,
and the most used imputation method is last observation carried forward (LOCF). LOCF is generally considered conservative,
but there are more reliable methods such as multiple imputation (MI).
Objectives: To compare four different methods of handling missing data in a 60-week placebo controlled anti-obesity drug
trial on topiramate.
Methods: We compared an analysis of complete cases with datasets where missing body weight measurements had been
replaced using three different imputation methods: LOCF, baseline carried forward (BOCF) and MI.
Results: 561 participants were randomised. Compared to placebo, there was a significantly greater weight loss with
topiramate in all analyses: 9.5 kg (SE 1.17) in the complete case analysis (N = 86), 6.8 kg (SE 0.66) using LOCF (N = 561), 6.4 kg
(SE 0.90) using MI (N= 561) and 1.5 kg (SE 0.28) using BOCF (N= 561).
Conclusions: The different imputation methods gave very different results. Contrary to widely stated claims, LOCF did not
produce a conservative (i.e., lower) efficacy estimate compared to MI. Also, LOCF had a lower SE than MI.
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Introduction
Attrition has been described as the bane of clinical trials on anti-
obesity drugs [1]. In most studies more than one third of the
participants have dropped out after one year [2], and in most
cases, missing data leads to bias [3]. Missingness can be classified
as missing completely at random (MCAR), missing at random
(MAR), or missing not at random (MNAR). In case of MCAR
missingness is independent of any observed or unobserved data,
e.g. a blood sample that is accidentally dropped on the floor. Only
when missingness is MCAR, the use of a complete case analysis of
the data, obtained exclusively from participants with all data
observed, may give an unbiased result. However, in most studies
MCAR is not the case [4]. When missingness is MAR, missingness
depends on the observed data, e.g. people with the smallest
treatment effect quit the trial. Finally, when missingness is MNAR,
it also depends on some unobserved data, e.g. people with an
unregistered latent depression quit the trial due to mood changes.
One of the most commonly applied methods for handling
attrition in obesity research is ‘last observation carried forward’
(LOCF) [2] where a missing weight measurement of a participant
at the end of trial is replaced by the participant’s last observed
value. To assume that one’s weight is unchanged after dropping
out of a trial seems hard to justify, as participants tend to regain
much of their lost weight within a short period of time after having
stopped the intervention [5]. Therefore, ’baseline carried forward’
(BOCF) has been proposed as a more reliable imputation strategy
[6]. However, both BOCF and LOCF overestimate the precision
of the effect estimate because the dataset is analysed, after single
imputation of the missing data, as if it was a ‘complete’ dataset
with no missing data [7]. Also intuitively, as one has doubts about
the imputed data, the p-values and confidence interval should be
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larger than those computed. Therefore, BOCF and LOCF both
provide undue certainty of the effect estimate even under MCAR
assumptions.
There are more reliable techniques for handling missing data
[8], and they can also be used when missingness is MAR.
Attention has been drawn to the multiple imputation (MI)
technique [9], which for some time has been recommended for
handling missing data in obesity trials [2]. The multiple
imputation technique is a stepwise procedure. First, based on the
observed data, a plausible multivariable distribution for the
missing values is estimated and they are being replaced by values
randomly drawn from this distribution resulting in a complete
dataset. Second, this procedure is repeated multiple times
generating multiple datasets. Third, the datasets are then analysed
separately producing multiple estimates, and fourth, the multiple
estimates are pooled resulting in one single estimate. Compared to
LOCF and BOCF, the precision will be more realistically
estimated because the uncertainty of the imputed values is taken
into account.
We had access to individual patient data from a large
randomised three-armed weight loss maintenance trial that
compared diet plus topiramate (96 mg or 192 mg) with diet plus
placebo (clinicaltrials.gov PRI/TOP-INT-35) [10]. Our primary
aim was to analyse the weight change and compare the results by
using four different methods for handling missing data. We
analysed the dataset of complete cases and datasets where missing
weight measurements had been replaced using three different
imputation methods LOCF, BOCF and MI. Our second aim was
to report the results of the analysis of the primary outcome
measure at the time-point specified in the trial protocol. These
were not reported in the published paper [10], because of
premature trial termination due to low tolerability of the drug.
Material and Methods
The trial was a randomised weight loss maintenance trial
(n = 561) that compared placebo (n= 187) with topiramate 96 mg
(n = 190) and 192 mg (n= 184) per day. It was designed to run for
a total of 82 weeks; an 8-week non-pharmacological low-calorie
diet run-in phase followed by randomisation, a 60-week interven-
tion phase, a 2-week drug tapering period and 12-week follow-up
period. The data included assessments of weight from 26 visits plus
standard baseline values (age, height, sex, etc.), a variety of blood
sample analyses and measures of hip and waist circumferences.
Each visit corresponded to a specific number of weeks in the trial.
More details about the methodology have been published
previously [10]. The authors of the published trial report wanted
to reduce the risk of bias due to premature trial termination and
therefore chose to analyse only a subset of people who had
received at least one dose of study drug, had provided at least one
post-baseline efficacy evaluation, and had the opportunity to
complete 44 weeks of treatment before the study closedown
announcement. They only allowed data collected before the
closedown announcement and up to week 44 to be included in the
analysis of efficacy. The primary outcome was percent weight
change from enrolment to the end of the intervention phase after
60 weeks of treatment, but this has not been published.
Data
Data was provided by the first author (AA) of a previous report
of this trial [10] and imported to SPSS 18.0.
Missingness
We assessed the mechanism of missingness by using Little’s test
[11] and by plotting mean weights of people with missing data
with those with data. Little’s test is essentially a Chi-square test on
whether the complete cases actually consist of a sample chosen
completely at random (MCAR) from the intention-to-treat
population considering the variables measured on the patients
with missingness. P,0.05 excludes a scenario due to MCAR and
makes the scenario missing at random (MAR, i.e. missingness is
explained by measured variables) more likely, although a scenario
of missing not at random (MNAR, i.e. missingness depending on
some unobserved variable), can never be totally excluded.
Comparison of imputation methods
We used the data from baseline (randomisation, week 0) to end
of treatment (week 60). For simplicity, we pooled the topiramate
arms. We analysed the mean weight change in the placebo and the
pooled topiramate group and the difference between the two from
baseline to end of treatment. We also analysed percentage change
in the same way. The results were plotted against time for
comparisons between the four analysis methods. We used the t-test
to calculate p-values.
Complete case analysis
This did not involve any imputation and was an analysis of data
from participants on intervention, i.e. all available data from
baseline to end of treatment.
Last observation carried forward
We substituted missing weight measurements with the last
observed measurement. We allowed carrying forward the baseline
value if this was the last observed measurement.
Baseline carried forward
We substituted missing weight measurements with the baseline
weight.
Mutiple imputation
We imputed the missing weight measurements with values of
weight obtained by the ‘Fully conditional specification method’ in
SPSS ver. 18. This is an iterative Markov chain Monte Carlo
method that can be used when the pattern of missing data is
monotone (i.e. a subject attends all visits till a visit is missed and
never returns) or none-monotone [12]. We used a linear regression
model that contained the variables: intervention group, sex, race,
age and baseline values (height, waist circumference, plasma
glucose, triglycerides, HDL-cholesterol, HDL/LDL-ratio, insulin,
haemoglobin and haemoglobin A1c). Additionally, we included
body weight, but only at visits prior to the visit of interest. For
example, we only included weight measurements from baseline to
week 20 for the imputation at week 20. We log-transformed weight
to satisfy the normality assumption which seemed to hold when we
assessed Q-Q plots and used the Kolmogorov–Smirnov test (p.
0.2, df = 561), but not the Shapiro–Wilk test (p = 0.04, df = 561).
We also assessed convergence by plotting the means and standard
deviations by iteration and imputation. The default number of 10
iterations in SPSS 18 seemed to be too low (File S1) as the
standard deviation gradually increased up till and stabilized at 400
iterations. Therefore we chose 500 iterations and 10 imputations
assuring an efficiency of the imputation of 99%.
Obesity
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The primary outcome measure at 60 weeks in the trial
protocol
We estimated the mean percent weight change from enrolment
(week –8) to end of treatment using the same methods as described
above. For completeness, we also re-analysed the data on the
subset of people previously published [10]). Using the criteria
above, it was not possible to get the exact same subset, but when
we allowed data collected 3 days after the closedown announce-
ment to be included in the analysis we came close.
Results
Details about the study population have previously been
published [10]. Baseline characteristics are available in File S1
and include the variables used in our analyses after MI.
Missingness
Missing data on weight gradually increased from week 0 to 44
(from 0% to 27%), and then increased markedly (Figure 1); only
15% (n= 86) of the participants were still on treatment and had
their weight recorded at the end of treatment. The reason for
missingness varied, but although it was mostly caused by
premature trial termination [10], the mechanism was unlikely to
be MCAR (P,0.01; Little’s test)(11). At most visits, participants
who missed the following visit seemed to weigh more than those
who attended (Figure 1).
Comparison of imputation methods over time and with
increasing missingness
From baseline to week 44, the estimated difference in mean
weight change between placebo and topiramate increased by all
four methods. From week 44 to end of treatment, the difference
increased in the complete case analysis and in LOCF, but
decreased in MI and BOCF (Figure 2). From baseline to end of
treatment the complete case analysis estimated the greatest
difference in weight loss (9.5 kg) and BOCF the smallest (1.5 kg).
MI and LOCF were similar with MI resulting in a slightly greater
difference from the beginning and throughout most of the trial and
a slightly smaller difference at the end of treatment (6.4 kg)
compared to LOCF (6.8 kg).
These differences were a result of an overall weight loss in the
topiramate group (Figure 3) and weight gain in the placebo group
(Figure 4). At the end of treatment the weight loss within the
pooled topiramate group was again biggest in the complete case
analysis (5.9 kg) and smallest in the BOCF (0.9 kg). Also, MI and
LOCF estimated a similar weight loss in the beginning of the trial,
but at the end of treatment MI (3.4 kg) showed a much smaller
weight loss than LOCF (5.5 kg) (Figure 3). The change within the
placebo group was similar in the complete case analysis and
BOCF in the beginning, but at the end of treatment the complete
case analysis estimated the biggest weight gain (3.7 kg) and BOCF
the smallest (0.5 kg). In the placebo group, MI and LOCF were
similar in the beginning, but at the end of treatment MI (3.0 kg)
showed a greater weight gain than LOCF (1.3 kg at week 60)
(Figure 4).
We got similar results when we analysed the percentage change
from baseline (data not shown).
The trial’s primary outcome measure at 60 weeks
The primary outcome measure at end of trial according to the
trial protocol was the percentage change from enrolment (week –8)
to end of treatment (week 60), and for placebo compared to
topiramate 96 mg the mean difference in weight loss was 10.5%
(SE =2.2%) in the complete case analysis, 6.1% (SE = 0.7%)
using LOCF, 5.5% (SE =1.1%) using MI and 1.7% (SE = 0.4%)
using BOCF. For placebo compared to topiramate 192 mg/day,
the mean difference was 10.0% (SE = 1.9%), 7.5% (SE = 0.8%),
7.3% (SE = 1.0%) and 1.5% (SE = 0.4%) using complete case
analysis, LOCF, MI and BOCF, respectively (Table 1). To check
the robustness of the findings of this analysis, we also pooled the
topiramate groups in a sensitivity analysis and the results were
similar (File S1).
When we re-analysed the percentage change from enrolment to
week 44 of the subset of participants, our results were similar to
those published previously (File S1).
Figure 1. Mean weight of participants attending or missing the next visit. Some patients return after a missed visit. Therefore no change in
number of patients at week 28 and 32.
doi:10.1371/journal.pone.0111964.g001
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Discussion
We compared 4 methods of analysing the effect of topiramate in
a weight loss trial. We found that, in the beginning of the trial,
LOCF and MI estimated similar body weight changes, but over
time and with high attrition they estimated different changes. This,
however, did not have a substantial impact on the difference in
body weight change between topiramate and placebo, which was
similar throughout the trial.
Complete case analysis estimated the greatest difference and
BOCF the smallest. We also estimated the weight change as
originally planned in the trial protocol as it was done in a previous
publication of the trial [10], and our results confirmed, regardless
of method, that in this trial topiramate produces a greater weight
loss than placebo. Other placebo-controlled trials have also shown
that topiramate reduces weight [13].
In several simulation studies, MI has been shown to provide a
more accurate and broader confidence interval and a less biased
estimate of the intervention effect than both complete case analysis
and single imputations [14][15][16]. In these studies, the method
has been to simulate missingness based on a complete dataset and
to use different imputation techniques to calculate an estimate of
the intervention effect from the imputed dataset. Thus, these
studies have been able to evaluate how close the result of an
imputation method comes to the correct estimate from the original
complete dataset. The results of such simulation studies have been
overwhelmingly in favour of MI.
In trials on anti-obesity drugs, it has previously been shown that
the LOCF estimates similar effect sizes, but overestimates the
Figure 2. Analysis of difference in weight loss between placebo and topiramate pooled (96 and 192 mg/day) from baseline to week
60 using different methods.
doi:10.1371/journal.pone.0111964.g002
Figure 3. Analysis of weight loss over time in topiramate pooled (96 or 192 mg/day) group using different imputation methods.
doi:10.1371/journal.pone.0111964.g003
Obesity
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precision, compared to MI [2][8]. It is therefore wrong to describe
LOCF as a conservative analysis, although this is often done.
Our results can be interpreted in relation to the per-protocol
(PP) assumption that all participants adhere to treatment, which is
an unrealistic scenario in trials on anti-obesity drugs, or the
intention-to-treat (ITT) method that assumes that some partici-
pants do not adhere to treatment. Thus the PP analysis estimates
the weight loss as if the participants adhere to the treatment and
the ITT analysis estimates the weight loss of the intention to give
the treatment regardless of adherence [17].
If a drug truly reduces the weight, the BOCF will yield a
conservative estimate (smaller weight loss) than a PP analysis, but
maybe a realistic estimate compared to an ITT analysis [6], as it is
likely that participants regain some of their body weight when they
stop treatment [5].
The interpretation of the LOCF analyses is difficult due to the
course of weight change during a weight loss trial. Most of the
weight loss occurs early on, then levels out and some is regained at
the end of the trial [18]. Compared with a PP analysis, it may be
reasonable to assume that LOCF underestimates the weight loss in
the short term and overestimates it in the long term. On the other
hand, compared with an ITT analysis, it is likely that LOCF
overestimates the weight loss and therefore BOCF should be
preferred for LOCF.
Our MI analysis is more compatible with the PP assumption
than the ITT assumption [17], because the imputations were
based on participants who were on treatment, topiramate or
placebo. If we had had complete data on some of the participants
that dropped out or did not adhere to the treatment, we could
have used their data for MI, which would then have reflected an
ITT analysis [17]. When no such data is available the MI analysis
is clearly preferable to the biased PP analysis that only includes
participants that have adhered to the protocol, but readers and
researchers need to think carefully about the analytic assumption
(e.g., PP versus ITT) used in an obesity trial.
Theoretically, the complete case analysis can occasionally be an
unbiased PP analysis, but only when the participants in the
analysis can be regarded as a random sample of the study
population (when the missing mechanism is MCAR, which is
rarely the case [4]). In our dataset, the missing mechanism was not
MCAR. It seemed that those who had missing data weighed more
than those without and thus the complete case analysis overesti-
mated the weight loss.
Results from weight loss trials are often inadequately reported.
The weight change within the treatment groups is stated and the
p-value may be the only result reported from the comparison
between the groups. Sometimes only the difference in weight
change between the groups is stated. We have reported body
weight change within the groups and between the groups, but also
Figure 4. Analysis of weight loss over time in the placebo group using different imputation methods.
doi:10.1371/journal.pone.0111964.g004
Table 1. Percentage weight change from enrolment (- 8 week) to end of treatment (week 60).
Placebo Mean (SE) Topimarate 96 mg Mean (SE) Topimarate 192 mg Mean (SE)
Completers 27.1 (1.40) (n = 28) 216.2 (1.58) (n = 31) 216.1 (1.48) (n = 27)
LOCF 29.2 (0.54) (n = 187) 214.7 (0.52) (n = 190) 216.2 (0.65) (n = 184)
MI 27.7 (0.68) (n = 187) 212.6 (0.75) (n = 190) 214.6 (0.76) (n = 184)
BOCF 29.8 (0.26) (n = 187) 211.3 (0.33) (n = 190) 211.5 (0.30) (n = 184)
SE: standard error.
For each difference (topiramate - placebo), P,0.001 (t-test).
doi:10.1371/journal.pone.0111964.t001
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p-values and CI-intervals. We found that MI and LOCF resulted
in similar differences between topiramate and placebo, but that the
weight change within the groups was smaller in the MI analysis
than in LOCF and this difference increased over time and with
increasing missing data. The most likely explanation for this is that
LOCF, but not MI, ignores the course of weight change (described
above) and that the bias LOCF introduces is more or less the same
in both treatment groups. Further, MI introduced greater but
more realistic uncertainty of the intervention effect estimate than
LOCF and BOCF; analyses using LOCF and BOCF can therefore
lead to spuriously significant results.
Limitations
As we do not know the true effect of topiramate or the body
weight of the missing participants, it is impossible to validate our
findings against a gold standard. Also, we do not know the exact
mechanism of missingness. If the mechanism is MNAR, all
imputation methods are likely to be biased. However, MI may
provide less biased results in this situation as well [16].
Another limitation is that many data were missing simply
because the trial was terminated prematurely, which is not a
common reason for attrition in obesity trials. The reason for
termination was harms. As we did not include harms in our
imputation model, missingness could be related to data that are
‘unobserved’ by the MI procedure. On the other hand, the harms
could be correlated to the variables we used; in fact, Figure 1
shows that missingness could be predicted by the weight of the
participants. This suggests that people experiencing similar harms
are more likely to stay in the trial if they have perceived an effect
on their weight.
Suggestions for improved research
The major reason for missing data when participants quit the
treatment is their lack of interest for having their weight measured
and for obvious reasons trialists cannot force the patient to show
up for a visit. Therefore we need weight loss trials that include
incentives for participants to be followed up and other logistic
methods for measuring the weight and side effects of those
participants who decide to quit treatment.
Most trial protocols specify that investigators shall do their best
to have a measurement at the end of the specified period, but
usually do not provide incentives or methods. The protocol for the
current trial stated that, ‘‘Participants withdrawn from the study
prior to completion of treatment period will be encouraged […] to
attend study visits with assessments equivalent to those performed
at Visit 23 [end of treatment]’’
The protocol for the RIO-North America trial of rimonabant
had a similar statement [19]: ‘‘For patients with premature
treatment discontinuation or patients considered lost to follow-up,
the [case report form] must be filled in up to the last visit
performed. The Investigator should make every effort to re-
contact and to identify the reason why the patient failed to attend
the visit and to determine his/her health status and to retrieve
study medication.’’
When the RIO-trial was published it was criticised in an
editorial for only measuring those participants that completed the
trial (53%) rather than all patients that were not lost to follow-up
(93%) [18]. It is indeed possible to have a high follow-up as seen in
a recently published weight loss trial of free meals and an intensive
weight loss program. After 24 months the investigators had weight
data on 92% of the study participants [20]. If participants don’t
attend the last visit, one might also contact them by phone and ask
them to use their own scale at home. Despite a trend that self-
reported weight is underestimated [22], this strategy may still be
reliable when comparing intervention and control groups, because
the bias introduced is likely to be similar in both groups.
Selective reporting of favourable analyses also occurs. In a
placebo-controlled trial of long-term treatment with sibutramine,
the authors only published an unadjusted ITT analysis (LOCF)
(n = 464). Compared to placebo the body weight reduction with
sibutramine 15 mg was 4.8 kg (p,0.001) and with 10 mg 2.8 kg
(p,0.01) [21]. In a trial report of the same study submitted to the
Danish Medicines Agency, an adjusted analysis of all available
participants (including those who were withdrawn) that had their
body weight measured at end of treatment (n = 305), showed
smaller weight reductions, 3.0 kg (p,0.001) and 2.1 (p,0.01) kg,
respectively.
When imputation is undertaken, more reliable techniques, such
as MI, should be used and to make a proper ITT analysis,
imputation should also be based on weight data collected after
withdrawal In general, MI is considered one of the most reliable
methods for imputing missing data. It has been available for more
than 20 years and in standard statistical programs for about 10
years. But MI is rarely used in randomised trials and has only
recently been proposed for trials on anti-obesity drugs [2]. There
has been and still is a steadfast tradition of using LOCF in these
trials, but policy is changing. The European Medicines Agency has
from 2011 implemented a guideline for handling missing data in
clinical trials [23] that the drug industry has to follow. The
guideline does not find LOCF, (but BOCF) appropriate for
chronic conditions such as obesity where the weight will be
expected to return to baseline when the treatment is stopped and it
describes MI as a more proper imputation technique. Therefore,
we assume that we will see more trials using BOCF and MI in the
future. With these changes, drug companies will be more
motivated for minimising attrition and missing data because
increasing attrition and missing data will result in a treatment
effect that approaches zero when BOCF is used.
Conclusions
The different imputation methods gave different results, but all
showed that topiramate reduced weight compared to placebo. In
anti-obesity trials, imputation is obligatory due to the amount and
type of missing data and because the complete case analysis is
biased. However, the ITT analysis using LOCF, which in general
is considered a conservative analysis, overestimated the precision.
We suggest that post withdrawal weight data must be obtained to
make a proper ITT analysis.
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